THACI, D.; PAPP, K.; GORDON, K.; MORITA, A.; GOODERHAM, M.; FOLEY, P.; ALEMANO, E.; KISA, R.; ELBEZ, Y.; REN, H.; BANERJEE, S. An oral, selective tyrosine kinase 2 inhibitor, BMS-986165, improves quality of life in psoriasis: results from a Phase 2 study. SKIN The Journal of Cutaneous Medicine, v. 3, p. S12, 9 Nov. 2019.